PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2

Blockade antibodies of the immunoinhibitory receptor PD-1 can stimulate the anti-tumor activity of T cells, but clinical benefit is limited to a fraction of patients. Evidence suggests that BTLA, a receptor structurally related to PD-1, may contribute to resistance to PD-1 targeted therapy, but how...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiaozheng, Hou, Bowen, Fulzele, Amitkumar, Masubuchi, Takeya, Zhao, Yunlong, Wu, Zijun, Hu, Yanyan, Jiang, Yong, Ma, Yanzhe, Wang, Haopeng, Bennett, Eric J., Fu, Guo, Hui, Enfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265324/
https://www.ncbi.nlm.nih.gov/pubmed/32437509
http://dx.doi.org/10.1083/jcb.201905085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265324/
https://www.ncbi.nlm.nih.gov/pubmed/32437509
http://dx.doi.org/10.1083/jcb.201905085

Ejemplares similares